Stockscreener 앱 받기
9.09
5.09%
0.44
시장 영업 전:
9.00
-0.09
-0.99%
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
XLO|Xilio Therapeutics Inc|Price:9.132|Chg%:+0.482 - TradingKey
Xilio Therapeutics Inc (XLO) Cash Flow - TradingKey
Xilio Therapeutics Inc (XLO) Balance Sheet - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xilio Therapeutics Inc (XLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Xilio Therapeutics, Inc. Revenue Breakdown – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc. (XLO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to earnings forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics (XLO) Holds Near Support After Modest DeclineRTH Profile - dars.gov.et
Xilio Therapeutics (XLO) Holds Steady Near Resistance – Biotech Stock in Tight RangeInsider Selling Alerts - dars.gov.et
XLO Stock Price, Quote & Chart - ChartMill
Xilio Therapeutics (XLO) Slides 2% as Biotech Stock Tests Key Support LevelsVolume Rate Change - dars.gov.et
Enterprise value to EBIT forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Therapeutics (XLO) Slides as Biotech Sector Headwinds PersistVolume Profile - dars.gov.et
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to sales forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com - Investing.com Nigeria
Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer - marketscreener.com
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - citybiz
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - Investing.com
Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief - Stock Titan
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Optimism Amid Pipeline ProgressEPS Estimate Trend - dars.gov.et
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell Microcap Index - marketscreener.com
Enterprise value to revenue forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell 3000E Value Benchmark - marketscreener.com
XLO Forecast — Price Target — Prediction for 2027 - TradingView
Xilio Therapeutics Inc Actuals & Estimates (NASDAQ:XLO) - TradingView
Xilio Therapeutics Inc (XLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XLO Price Today: Xilio Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Xilio Therapeutics Inc (XLO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xilio Therapeutics Inc (XLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xilio Therapeutics Inc (XLO) Institutional Confidence - TradingKey
Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes - The Globe and Mail
Daniel Curran reappointed to Class III director at Xilio - TradingView
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options - Stock Titan
Xilio (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Xilio Therapeutics (XLO) director Xu Yuan receives grant of 5,000 stock options - Stock Titan
Xilio Therapeutics (XLO) director receives 5,000 stock options at $7.99 strike - Stock Titan
Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99 - Stock Titan
Board changes and stock plan vote at Xilio Therapeutics (NASDAQ: XLO) - Stock Titan
Top Lunai Bioworks (LNAI) Competitors 2026 - MarketBeat
Xilio Therapeutics (XLO) Edges Higher, Testing Resistance After Modest GainsVolume Gap - dars.gov.et
1.97%
0.83%
자본화:
|
볼륨(24시간):